Amylyx Pharmaceuticals

US · AMLX #2392 by market cap Listed 2022

27.43 -0.61 -2.18%

Live - 5344 symbols - heartbeat 420s ago · 2026-10-08 07:11

Pre-market 27.47 +0.15%

After-hours 27.43 0.00%

Market cap: 3.44B
P/E (TTM): -19.45
P/B: 14.39
EPS: -1.53
Div yield: 0.00%
52W pos: 55%

Reader sentiment Are you bullish or bearish on AMLX?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing

The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
Total institutional ownership fell 14.9 percentage points.

Institutional ownership

Held by institutions: 91.78% -14.89pp
Institutions: 237 -2
As of: 2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Mutual Fund52.37%

Hedge Fund20.04%

VC/PE Fund13.50%

Individual/Insider6.08%

Public Company4.50%

Private Company0.92%

Government Pension Fund0.23%

Sovereign Wealth Fund0.13%

Other2.17%

Top holders as of 2026-06-30

FMR 13.33% · 16.73M sh

BlackRock 7.03% · 8.83M sh

Perceptive Advisors LLC 6.64% · 8.33M sh

TCG Crossover Management, LLC 4.97% · 6.24M sh

Commodore Capital LP 4.50% · 5.65M sh

Janus Henderson Group plc 4.17% · 5.24M sh

Vanguard Capital Management, LLC 3.86% · 4.85M sh

Saturn V Capital Management LP 3.68% · 4.62M sh

Joshua Cohen 2.51% · 3.15M sh

Justin Klee 2.51% · 3.15M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 24 buys · 26 sells

Name	Role	Stake
Joshua Cohen	Co-Chief Executive Officer	2.51%
Justin Klee	Co-Chief Executive Officer	2.51%
George Milne	Independent Chairperson	0.65%
James Frates	Chief Financial Officer	0.18%
Karen Firestone	Independent Director	0.09%
Camille Bedrosian	Chief Medical Officer	0.08%
Gina Mazzariello	Chief Legal Officer & General Counsel	0.04%
Bernhardt G. Zeiher	Director	0.01%
Daphne Quimi	Independent Director	0.00%
Paul Fonteyne	Independent Director	0.00%

Insider transactions most recent Form 4 filings

Date	Name	Role	Type	Shares	Price
2026-09-09	James Frates	Chief Financial Officer	Private Disposition	-1,042	$33.23
2026-09-09	James Frates	Chief Financial Officer	Open Market Disposition	-9,768	$32.27
2026-09-09	Camille Bedrosian	Chief Medical Officer	Private Disposition	-2,081	$33.09
2026-09-09	Camille Bedrosian	Chief Medical Officer	Open Market Disposition	-7,947	$32.21
2026-09-09	Joshua Cohen	Co-Chief Executive Officer	Private Disposition	-919	$33.15
2026-09-09	Joshua Cohen	Co-Chief Executive Officer	Open Market Disposition	-29,545	$32.16
2026-09-09	Justin Klee	Co-Chief Executive Officer	Private Disposition	-1,439	$33.16
2026-09-09	Justin Klee	Co-Chief Executive Officer	Open Market Disposition	-29,025	$32.13
2026-09-09	Gina Mazzariello	Chief Legal Officer & General Counsel	Private Disposition	-11	$33.34
2026-09-09	Gina Mazzariello	Chief Legal Officer & General Counsel	Open Market Disposition	-9,525	$32.46
2026-08-30	Karen Firestone	Independent Director	Derivative Exercise and Retained	+50,000	$1.76–5.05
2026-08-17	James Frates	Chief Financial Officer	Other Acquisition	+22,807	--
2026-08-17	Camille Bedrosian	Chief Medical Officer	Other Acquisition	+22,807	--
2026-08-17	Joshua Cohen	Co-Chief Executive Officer	Other Acquisition	+60,039	--
2026-08-17	Justin Klee	Co-Chief Executive Officer	Other Acquisition	+60,039	--
2026-08-17	Gina Mazzariello	Chief Legal Officer & General Counsel	Other Acquisition	+21,284	--
2026-07-09	Gina Mazzariello	Chief Legal Officer & General Counsel	Open Market Disposition	-30,000	$17.61–18.32
2026-07-08	Gina Mazzariello	Chief Legal Officer & General Counsel	Intent to Sell (Form 144)	-30,000	$17.88
2026-06-03	George Milne	Independent Chairperson	Other Derivative Acquisition	+24,372	$14.31
2026-06-03	Karen Firestone	Independent Director	Other Derivative Acquisition	+24,372	$14.31

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 07:11:36 · For reference only, not investment advice and not tailored to your situation.